Viva Biotech Holdings
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VBIZF research report →
Price Chart
About the company
As an investment holding enterprise, Viva Biotech Holdings provides comprehensive drug discovery services, leveraging a structure-based approach for biotechnology and pharmaceutical clients across the globe. Their offerings encompass discovery biology, including protein expression and purification, structural biology, identification of promising drug candidates (hit discovery), bioassay development, analysis of biomolecular interactions, and pharmacokinetics. They also deliver a range of chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, preparation for purification, and computer-aided drug design (CADD), supported by advanced chemical technology platforms.
- CEO
- Chen Cheney Mao
- IPO
- 2019
- Employees
- 2,169
- HQ
- Shanghai, SH, CN
Get TickerSpark's AI analysis on VBIZF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $396.90M
- P/E
- 15.86
- Fwd P/E
- 1.53
- PEG
- 18.45
- P/S
- 1.43
- P/B
- 0.69
- EV/EBITDA
- 6.53
- Div Yield
- 0.00%
- Gross Margin
- 34.55%
- Op Margin
- 10.05%
- Net Margin
- 9.36%
- ROE
- 4.45%
- ROIC
- 2.61%
Latest fiscal year · YoY change
- Revenue
- $1.68B-15.2%
- Gross Profit
- $638.64M-7.1%
- Op Income
- $188.26M
- Net Income
- $214.09M+28.0%
- EPS
- $0.10+27.7%
- OCF Growth
- -44.9%
- FCF Growth
- -51.7%
- 52W High
- $0.43
- 52W Low
- $0.13
- 50D MA
- $0.18
- 200D MA
- $0.24
- Beta
- 1.38
- RSI (14)
- 80
- Avg Volume
- 176
No earnings-call transcripts are available for VBIZF yet.
- Free Float
- 48.7%
- Shares Outstanding
- 2.07B
- Float Shares
- 1.01B
Our VBIZF coverage
Recent articles, reports, and earnings notes.
No research on VBIZF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VBIZF report →Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up
prnewswire.com · Mar 30
Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
prnewswire.com · Mar 16
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
prnewswire.com · Dec 29
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
prnewswire.com · Dec 15
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
prnewswire.com · Sep 29
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
prnewswire.com · Sep 2
Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth
prnewswire.com · Aug 28
Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
prnewswire.com · Mar 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.